Related Experiment Videos
The new vaccines: building viruses that elicit antitumor immunity
1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. restifo@helix.nih.gov
Abstract:
Whereas cancer cells are poor immunogens, some viruses are capable of eliciting powerful and lifelong immunity. Recombinant viruses and plasmid DNA encoding tumor-associated antigens can elicit powerful and specific immune responses that can be enhanced by the use of cytokines and costimulatory molecules. These immune responses have destroyed growing tumor cells in experimental animal models. For the first time, immunotherapeutic strategies that employ recombinant viruses are being tested in clinical trials with cancer patients.
Insights
Recombinant viruses can be engineered to target cancer cells, stimulating powerful immune responses. These novel cancer immunotherapies are now being tested in clinical trials for patients.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Cancer cells typically do not trigger strong immune responses.
- Certain viruses naturally induce potent and lasting immunity.
Purpose of the Study:
- To explore the potential of recombinant viruses for cancer immunotherapy.
- To investigate methods for enhancing anti-tumor immune responses.
Main Methods:
- Utilizing recombinant viruses and plasmid DNA encoding tumor-associated antigens.
- Employing cytokines and costimulatory molecules to augment immune activity.
- Testing these strategies in experimental animal models.
Main Results:
- Demonstrated the ability of recombinant viruses to elicit powerful and specific immune responses.
- Showed destruction of growing tumor cells in experimental animal models.
- Successfully translated these immunotherapeutic strategies into clinical trials.
Conclusions:
- Recombinant viruses represent a promising approach for cancer immunotherapy.
- Enhancement strategies can significantly boost anti-tumor immunity.
- Clinical trials are underway to evaluate the efficacy in cancer patients.